August 26, 2022
EPS Holdings, Inc.

News release

Establishment of Intermediate Holding Company and Corporate Restructuring
EPS Holdings, Inc. (Head Office: Shinjuku-ku, Tokyo; President and Representative Director:
Hao YAN; hereinafter “EPSHD” or “the Company” ) hereby announces that it will establish anintermediate holding company that will manage the core businesses of the EPS Group via a sharetransfer to be conducted by EPS Corporation (Head Office: Shinjuku-ku, Tokyo; President andRepresentative Director: Akira Sasa; hereinafter “EPS”) and EP-SOGO Co., Ltd. (Head Office:Shinjuku-ku, Tokyo; President and Representative Director: Kenichi Yamamoto, hereinafter “EPSOGO”), which are subsidiaries of EPSHD. In addition, all the shares of EP Mediate Co., Ltd.
(Head Office: Shinjuku-ku, Tokyo; President and Representative Director: Masanori Tanji,
hereinafter “EPMD”) will be delivered to EPS by way of the share delivery method.
The name of the intermediate holding company to be established will be EPNextS Co., Ltd.,
which begins with an acronym of “Ever Progressing” from the Group’s Vision and adds “Next” torepresent the next generation, and then “S” to evoke the words “stage,” “system,” “solution,” and“structure.”
Thirty years after its founding, EPS Group is entering its next phase as a new solutions provider.
1. Purpose of Establishment of Intermediate Holding Company and Corporate
Restructuring
As a solutions provider that contributes to the development of the healthcare industry, theCompany possesses EPS, which handles the CRO*1 business, and EP-SOGO, which handles theSMO*2 business, under its umbrella, positioning both as core businesses, and it has worked toimprove services and expand its business matched to customer needs by capitalizing on
collaboration between the two core businesses and the know-how and product development
capabilities of other related businesses in the Group.
Against this backdrop, the EPS Group conducted a management buyout in the previous fiscal
year and is focusing on finding and establishing new revenue models while working to convert its
business structure in order to pursue the “four transformations” of its SHINYO medium-term
management plan. Under this policy, for both the CRO and SMO businesses, the Company believes
it will be necessary to ensure flexible strategic decision-making that takes into account overall
optimization in line with changes in the clinical research environment going forward and to strive tofurther strengthen management, and it has therefore decided to establish an intermediate holding

company that will manage both businesses.
In addition, EPMD, after starting operations, worked to expand its business as the Group’s CRO
for medical device development, health foods, diagnostic drugs, and other categories, but as a partof the reorganization of the CRO business coinciding with the establishment of the newintermediate holding company, all shares of EPMD, which are owned by the Company, will bedelivered to EPS.
Going forward, the intermediate holding company will play a central role in guidance, support,
and management for effective utilization of the management resources of the two companies andtheir subsidiaries, and for the companies’ operational management and strategy development. It will
also work to maximize corporate value by building a competitive business structure, which will
include strengthening risk management and governance.
Organizational Restructuring as of October 4, 2022

(Percentages are ownership stakes)

2. Overview of Entities Involved in Share Transfer
NameAddress
Representative
Director

EPS Corporation
2-23 Shimomiyabicho, Shinjuku-ku,TokyoAkira SASA

EP-SOGO Co., Ltd.
1-8 Tsukudocho Shinjuku-ku, Tokyo

Kenichi YAMAMOTO

Drug development support
Business area

Post-marketing surveillance support
Safety information management

Clinical trial facility support

supportCapital

100 million yen

100 million yen

Establishment

July 1, 2014

December 24, 1999

3. Overview of New Company to be Established via Share Transfer
Name

EPNextS Co., Ltd.

Address

2-1 Tsukudohachimancho, Shinjuku-ku, Tokyo

Representative
Director

Tatsuma NAGAOKAManagement strategy for the two companies, research on new services,

Business area

M&A strategy execution to help raise the added value of the two companies’
businesses, and related activities

Capital

100 million yen

Establishment

October 4, 2022

Main shareholder andownership stake

EPS Holdings, Inc., 100%

4. Overview of Entity to Which Shares Will be DeliveredName

EP Mediate Co., Ltd.

Address

1-8 Tsukudocho, Shinjuku-ku, Tokyo

RepresentativeDirector

Masanori TANJI
Medical device development support

Business area

Foods with Health Claims development support (food CRO)In vitro diagnostic development support
Drug analysis

Capital50 million yen

Establishment

October 1, 2018

Recipient of shares

EPS Corporation, 100%

*1: Contract research organization*2: Site management organization

Contact: EPS Holdings, Inc.
Corporate Communicates OfficeE-mail: pr@eps.co.jp